<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="remdesivir, and Kaletra were predicted to inhibit SARS-CoV-2. â€¢Rapamycin and" exact="tiotropium bromide" post="may also be effective for SARS-CoV-2. Abstract The infection"/>
 <result pre="against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM)," exact="efavirenz" post="(199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM)."/>
 <result pre="3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM)," exact="ritonavir" post="(204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir,"/>
 <result pre="remdesivir (113.13 nM), efavirenz (199.17 nM), ritonavir (204.05 nM), and" exact="dolutegravir" post="(336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all"/>
 <result pre="(204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and" exact="darunavir" post="are all designed to target viral proteinases. However, in"/>
 <result pre="analysis. The SARS-CoV-2 3C-like proteinase was predicted to bind with" exact="atazanavir" post="(Kd 94.94 nM), followed by remdesivir, efavirenz, ritonavir, and"/>
 <result pre="studies have been identified. For example, a docking study of" exact="lopinavir" post="along with other HIV proteinase inhibitors of the CoV"/>
 <result pre="HIV proteinase inhibitors of the CoV proteinase (PDBID 1UK3) suggests" exact="atazanavir" post="and ritonavir, which are listed in the present prediction"/>
 <result pre="the CoV proteinase in line with the inhibitory potency of" exact="lopinavir" post="[27]. According to the prediction, viral proteinase-targeting drugs were"/>
 <result pre="O)N1CC2C(C1C( O)NC(CC1CCC1)C( O)C(N) O)C2(C)C)C(C)(C)C 433.93 101 Among the prediction results," exact="atazanavir" post="was predicted to have a potential binding affinity to"/>
 <result pre="of the COVID-19 replication complex may be inhibited simultaneously by" exact="atazanavir" post="(Table 2, Table 3, Table 4, Table 5, Table"/>
 <result pre="2, Table 3, Table 4, Table 5, Table 6). Also," exact="ganciclovir" post="was predicted to bind to three subunits of the"/>
 <result pre="anti-HIV drug, Prezcobix of Johnson &amp;amp; Johnson, which consists of" exact="darunavir" post="and cobicistat, was to be sent to China [29],"/>
 <result pre="and cobicistat, was to be sent to China [29], and" exact="darunavir" post="is also predicted to have a Kd of 90.38"/>
 <result pre="3). However, there was no current supporting literature found for" exact="darunavir" post="to be used as a CoV therapeutic. Although remdesivir"/>
 <result pre="by inhibiting some aspects of SARS-CoV-2. For example, remdesivir and" exact="chloroquine" post="showed inhibitory effects against SARS-CoV-2 in vitro[31]. Another in-vitro"/>
 <result pre="effects against SARS-CoV-2 in vitro[31]. Another in-vitro study showed that" exact="hydroxychloroquine" post="was found to be more potent than chloroquine for"/>
 <result pre="showed that hydroxychloroquine was found to be more potent than" exact="chloroquine" post="for inhibiting SARS-CoV-2 [32]. Remdesivir and lopinavir/ritonavir (Kaletra) also"/>
 <result pre="but some differences were observed. For example, atazanavir, remdesivir, and" exact="efavirenz" post="were the top three predicted drugs that may bind"/>
 <result pre="that these drugs may be effective in inhibiting SARS-CoV-2. Lastly," exact="atazanavir" post="appears to be effective in the treatment of COVID-19"/>
 <result pre="issue)17145705 15PaoliniG.V.ShaplandR.H.van HoornW.P.MasonJ.S.HopkinsA.L.Global mapping of pharmacological spaceNat Biotechnol247200680581516841068 16WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="treatment of SARS: initial virological and clinical findingsThorax593200425225614985565 31WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
</results>
